ArticleBiosensors2025
Ultra-Sensitive Biosensors for Medical Applications Based on Nanomechanics: From Detection of Synthetic Biomolecules to Analysis of Sepsis in Pediatric Patients.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recent advancements in nanomechanical microcantilever biosensors open new possibilities for clinical applications, permitting precise analysis of molecular interactions. The technology enables tracking gene expression, molecular conformational changes, antibody binding and antibiotic resistance. In particular, hybridization of DNA or RNA extracted from biopsies and whole blood from patients has led to significant advancements in diagnostics of critical medical conditions, e.g., cancer, bacteraemia and sepsis, utilizing rapid, sensitive, and label-free detection. Direct diagnosis from patient samples is a decisive advantage over competitive methods circumventing elaborate and time-consuming purification, amplification and cultivation procedures prior to analysis. Here, recent developments are presented from simple DNA hybridization of synthesized oligonucleotides to RNA material obtained from patients' blood samples, highlighting technological advancements in diagnostic applications, such as detection of pathogens and disease biomarkers. We envisage our method to be a significant input to rapid, early and sensitive diagnosis directly from patients' blood without requirements for amplification or cultivation. This would represent a paradigm shift in diagnostics, as no competing method currently exists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.